Nuvation Bio Inc (NUVB)
NYSE:NUVB
Top Page
Nuvation Bio
(NYSE:NUVB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.50
▼(-2.17% Downside)
Action:ReiteratedDate:03/04/26
The score is primarily constrained by weak financial performance (large losses and cash burn despite improving revenue/gross margin) and a bearish technical setup (below key moving averages with negative MACD). These are partially offset by a constructive earnings-call outlook highlighting strong launch traction, supportive clinical data, and substantial cash resources.
Positive Factors
Revenue inflection & higher gross margin
A material revenue inflection with sharply improved gross margin indicates the company can monetize approvals and milestone events while achieving higher-quality revenue. This supports sustainable reinvestment in R&D/commercialization and reduces reliance on one-off financing over the medium term.
Negative Factors
Historic negative cash flow and burn
Sustained negative operating cash flows reflect development-stage economics and elevate dependence on milestones, partnerships, or equity financing. Even with current cash, ongoing burn increases execution risk and may constrain strategic choices if commercial scale-up is slower than planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue inflection & higher gross margin
A material revenue inflection with sharply improved gross margin indicates the company can monetize approvals and milestone events while achieving higher-quality revenue. This supports sustainable reinvestment in R&D/commercialization and reduces reliance on one-off financing over the medium term.
Read all positive factors
Nuvation Bio (NUVB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.60B
Dividend YieldN/A
Average Volume (3M)4.53M
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue Growth1137.19%
EPS Growth70.51%
CountryUS
Employees273
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding346,597,300
10 Day Avg. Volume2,869,970
30 Day Avg. Volume4,529,874
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue22.90
Enterprise Value/Gross Profit26.45
Enterprise Value/Ebitda-7.36
Forecast
1Y Price Target
$11.93Price Target Upside159.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$193.36M
Nuvation Bio Business Overview & Revenue Model
Company Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2,...
How the Company Makes Money
Nuvation Bio’s primary way of making money is through developing oncology drug candidates and, if/when they obtain regulatory approvals, commercializing those products (or monetizing them via licensing). As a clinical-stage company, it generally d...
Nuvation Bio Earnings Call Summary
Earnings Call Date:Mar 02, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call highlights a number of strong clinical and commercial progress points — U.S. approval of IBTROZI, rapid new patient starts (~6x faster vs. prior launches), compelling durability data (median DOR 50 months in TKI‑naive), broad payer access, strong cash position ($529.2M), and advancing pipeline programs (safusidenib Phase III initiation and a non‑pivotal cohort with potential accelerated pathway). Offsetting these positives are near‑term commercial headwinds: a mismatch between new patient starts and net product revenue due to an early mix skewed toward later‑line patients who discontinue quickly, rising gross‑to‑net (~25%), high operating costs (R&D $115.1M; SG&A $151.6M), a discontinued DDC candidate, and long timelines for pivotal readouts (safusidenib SIGMA readout expected 2029). Overall, the call projects long‑term upside driven by clinical differentiation and international partnerships while acknowledging short‑term revenue and execution uncertainties.Positive Updates
U.S. Approval and Strong Launch Momentum for IBTROZI
Received full U.S. FDA approval on June 11, 2025 for IBTROZI in advanced ROS1-positive NSCLC; 432 new patients started IBTROZI in 2025 (216 in Q4) and IQVIA shows prescriptions ~6x faster than the two prior ROS1 TKI launches over their first two full quarters.
Negative Updates
Revenue Growth Lag Behind New Patient Starts
Despite 432 new patient starts in 2025, net product revenue remained modest ($24.7M full year) because a large share of early launches were later‑line patients who discontinue quickly; company highlighted the launch mix (many third‑line+) as the main reason for a gap between new patient starts and revenue recognition.
Read all updates
Q4-2025 Updates
Positive
Negative
U.S. Approval and Strong Launch Momentum for IBTROZI
Received full U.S. FDA approval on June 11, 2025 for IBTROZI in advanced ROS1-positive NSCLC; 432 new patients started IBTROZI in 2025 (216 in Q4) and IQVIA shows prescriptions ~6x faster than the two prior ROS1 TKI launches over their first two full quarters.
Read all positive updates
Company Guidance
The company provided no formal 2026 revenue guide but gave clear operational and development milestones: commercial metrics include 432 new IBTROZI patient starts by year‑end 2025 (216 in Q4, 204 in Q3), an observed >200 new patient starts/quarter run rate to date, IQVIA showing prescription uptake ~6x faster than the two prior ROS1 TKI launches over their first two quarters, 70% of new starts from academic/IDN centers vs 30% community, specialty inventory of ~2–4 weeks, and Innovation Connect data showing ~75% of discontinuations coming from later‑line patients; clinical metrics include a pooled median DOR of 50 months and 89% confirmed ORR in TKI‑naive IBTROZI patients (clinical database of 337 with only 1 discontinuation for common AEs), ROS1 disease CNS burden (36% present with brain mets, brain is first site of progression in ~50% of cases), safusidenib Phase II (n=27) with median PFS not reached, ~12% progression at 24 months and 44% ORR, Phase I safusidenib ORR 17% (n=35) in high‑grade, ~8% drug‑related discontinuation at 250 mg BID, SIGMA Phase III sized at ~300 patients with a 2029 readout (no interim planned), and a non‑pivotal grade‑3 oligodendroglioma cohort ~40 patients (31 U.S. sites activated) targeting a 2027 readout; financial metrics/guidance include Q4 revenue $41.9M and FY2025 revenue $62.9M (IBTROZI net U.S. product revenue $15.7M Q4 / $24.7M FY), gross‑to‑net ≈25% (expected to tick up then stabilize), year‑end cash ~$529.2M with an additional $50M term loan available through June 30, 2026, Eisai upfront ~$60M (+ ~$30M on EU approval and up to ~$140M in sales milestones, plus double‑digit to high‑teens royalties) and a combined ex‑U.S. deal value of ~ $520M (ex‑LatAm), and the company expects no need for additional external financing to reach profitability under its current plan.Nuvation Bio Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 62.90M | 7.87M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 54.46M | 795.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -190.94M | -566.91M | -75.58M | -119.53M | -93.13M |
| Net Income | -204.63M | -567.94M | -75.80M | -104.20M | -86.85M |
Balance Sheet | |||||
| Total Assets | 594.82M | 540.63M | 621.48M | 672.14M | 776.15M |
| Cash, Cash Equivalents and Short-Term Investments | 529.21M | 502.69M | 611.21M | 661.01M | 765.39M |
| Total Debt | 10.15M | 8.91M | 4.01M | 4.26M | 3.06M |
| Total Liabilities | 289.11M | 76.84M | 16.36M | 17.07M | 30.15M |
| Stockholders Equity | 305.72M | 463.79M | 605.12M | 655.08M | 746.00M |
Cash Flow | |||||
| Free Cash Flow | -173.78M | -130.57M | -68.07M | -96.48M | -68.47M |
| Operating Cash Flow | -173.43M | -130.41M | -68.00M | -96.11M | -68.19M |
| Investing Cash Flow | 99.52M | 122.70M | 8.92M | 63.46M | -454.67M |
| Financing Cash Flow | 202.53M | 331.00K | 628.00K | 1.33M | 625.53M |
Nuvation Bio Technical Analysis
Positive
4.60
Price Trends
4.98
Negative
6.29
Negative
4.75
Negative
Market Momentum
-0.13
Negative
49.22
Neutral
69.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVB, the sentiment is Positive. The current price of 4.6 is above the 20-day moving average (MA) of 4.39, below the 50-day MA of 4.98, and below the 200-day MA of 4.75, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 49.22 is Neutral, neither overbought nor oversold. The STOCH value of 69.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUVB.
Nuvation Bio Risk Analysis
Nuvation Bio disclosed 89 risk factors in its most recent earnings report. Nuvation Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuvation Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $8.80B | -21.87 | -58.74% | ― | 364.98% | -25.33% | |
57 Neutral | $2.22B | -5.95 | -399.10% | ― | -32.79% | 36.87% | |
56 Neutral | $2.71B | -8.42 | -24.22% | ― | ― | 3.18% | |
52 Neutral | $1.35B | -14.03 | -84.99% | ― | 103.75% | 33.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.60B | ― | -57.48% | ― | 1137.19% | 70.51% | |
50 Neutral | $1.51B | -5.08 | -8396.72% | ― | 59.20% | -155.65% |
* Healthcare Sector Average
NUVB
Nuvation Bio
4.60
2.58
127.72%
NKTR
Nektar Therapeutics
77.50
68.44
755.60%
PGEN
Precigen
4.16
2.76
197.14%
WVE
Wave Life Sciences
7.18
1.18
19.67%
ELVN
Enliven Therapeutics
45.32
28.13
163.64%
PRAX
Praxis Precision Medicines
316.14
286.39
962.66%
Nuvation Bio Corporate Events
Business Operations and StrategyFinancial Disclosures
Nuvation Bio Expands Global Reach with Eisai Partnership
Positive
Jan 12, 2026
On January 11, 2026, Nuvation Bio entered into an exclusive license and collaboration agreement with Eisai granting Eisai rights to develop and commercialize taletrectinib (IBTROZI) across Europe, a wide swath of the Middle East and North Africa, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.